Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Data Submissions: FDA Tips For Navigating Committee Review

Executive Summary

Drug sponsors need to be pro-active and thorough in justifying their approach to pediatric studies in light of the added layer of review now conducted by the internal FDA Pediatric Review Committee, FDA's Lisa Mathis advised at the DIA annual meeting in Boston June 25

You may also be interested in...



Pediatric Study Plans Would Be Required At End Of Phase II Under Bipartisan House Bill

Rather than assessing monetary penalties for violating study deadlines, H.R. 4274 directs FDA to issue warning letters and publish them on its website.

Pediatric Review Committee

An internal panel of experts will provide advice on pediatric studies and exclusivities, FDA announces Oct. 25. Plans to have the new Pediatric Review Committee look over all written requests for pediatric studies prior to their issuance could help the agency define more precisely the studies it wants industry to perform (1"The Pink Sheet" July 2, 2007, p. 8). PeRC, which will be composed of representatives from CDER, CBER and the Commissioner's Office and will initially meet weekly, will also analyze the agency's past performance in implementing provisions of the Pediatric Research Equity Act concerning assessments of a drug's efficacy and safety in the pediatric population...

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel